Vinpocetine attenuates fluoxetine-induced liver damage in rats; Role of Nrf2 and PPAR-γ

Abstract

Background Fluoxetine (FLX) has been widely used as first-line treatment in cases of depression and other neuropsychiatric disorders. Although its safety has been approved, the use of FLX was associated with liver injury and chronic liver disease. Vinpocetine (Vinpo), a nootropic drug, possesses antioxidant and anti-inflammatory effects. Objective This study aimed to evaluate the protective effects of Vinpo on FLX-induced liver damage pointing to the role of peroxisome proliferator-activated receptor-gamma (PPAR-γ) and nuclear factor erythroid 2-related factor 2 (Nrf2). Methods Rats were randomized to four groups: control group, Vinpo group (20 mg/kg/day; orally), FLX group (10 mg/kg/day; orally), and Vinpo + FLX group. Results FLX-induced liver damage was evidenced through elevated liver function biomarkers and induced hepatic histopathological changes. Concurrent Vinpo treatment resulted in a significant decrease in hepatotoxicity biomarkers and histopathological alterations. FLX-induced oxidative stress and inflammation were attenuated by Vinpo. In addition, Vinpo attenuated the hepatic NRF2 and HO-1 levels and up-regulated PPAR-γ expression. Moreover, FLX elevated Bcl-2-associated X protein (Bax) mRNA expression and decreased B-cell lymphoma 2 (Bcl2) mRNA expression were markedly reversed by Vinpo. Conclusion Vinpo possesses ameliorative effects against FLX-induced liver injury in rats. This effect may be due to attenuation of oxidative stress and inflammation, in addition to upregulation of PPAR-γ expression.

Vinpocetine alleviated alveolar epithelial cells injury in experimental pulmonary fibrosis by targeting PPAR-γ/NLRP3/NF-κB and TGF-β1/Smad2/3 pathways

“…Reports have shown that PPAR-γ and PDE1 have a complex relationship that affects various physiological and pathological processes. Inhibition of PDE1 can enhance the expression and activity of PPAR-γ, which improves glucose and lipid metabolism and anti-inflammatory activity supported by previous studies 76 , 77 . NLRP3 and NF-κB complement one another, where NLRP3 is a cytosolic protein complex that forms an inflammasome in response to various stimuli, such as pathogens, toxins, or cellular stress.…”

PPAR-γ Activation Alleviates Osteoarthritis through Both the Nrf2/NLRP3 and PGC-1α/Δψm Pathways by Inhibiting Pyroptosis

“…Nevertheless, an opposite expression variation between Nrf2 and PPAR- γ has been discovered. Vinpocetine as a nootropic drug attenuated Nrf2 and increased PPAR- γ level in fluoxetine-induced liver damage of rats [ 53 ]. PPAR- γ can regulate the endogenous catalase [ 54 ].…”

Protective Effect of Combined Metoprolol and Atractylenolide I in Rats with Acute Myocardial Infarction via Modulation of the SIRT3/β-CATENIN/PPAR-γ Signaling Pathway

“…Β-catenin promotes transdifferentiation of myocardial fibroblasts and can induce myocardial damage (Piven, Winata, 2017;. Peroxisome proliferator-activated receptor gamma (PPAR-γ), as a member of the nuclear receptor transcription factor superfamily, is known to inhibit cardiomyocyte injury (Mohamed Kamel, 2021;Paciello et al, 2021). Furthermore, β-catenin can directly regulate PPAR expression in cardiomyocytes and is regulated by SIRT3 (Song et al, 2019).…”